Pharmacovigilance in developing countries (part I): importance and challenges
- 725 Downloads
The thalidomide disaster was the significant historical event that acted as a catalyst for pharmacovigilance activity. Following this event developed countries initiated drug monitoring systems that evolved and now extend their scope to broader drug-related safety issues; however, this was not the case in developing countries. Pharmacovigilance is still a relatively new concept with low priority in developing countries although various issues are raising concerns that magnify the need for systems to monitor post marketing drug safety in these countries. This article analyzes the barriers to introducing robust pharmacovigilance systems in developing countries.
KeywordsAdverse drug reactions Developing countries Drug safety Pharmacovigilance Post marketing monitoring
The author would like to thank Professor Maggie Huff-Rousselle for her contributions. Also, very special thanks go to Mahmoud Ahmed, Johannah Segarich, and all professors, staff, and colleagues at Massachusetts College of Pharmacy and Health Sciences University.
Conflicts of interest
The authors declare that they have no competing interests.
- 1.World Health Organization. Pharmacovigilance: Ensuring the safe use of medicines. http://www.who-umc.org/graphics/24753.pdf. Accessed Nov 2015.
- 4.Saito M, Hirata-Koizumi M, Miyake S, Hasegawa R. Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States. Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku. 2005;123:41–5.Google Scholar
- 9.International Conference on Harmonisation. Ethnic factors in the acceptability of foreign clinical data E5 (R1). http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E5_R1/Step4/E5_R1__Guideline.pdf. Accessed Feb 2016.
- 12.World Health Organization. The importance of pharmacovigilance. http://apps.who.int/medicinedocs/pdf/s4893e/s4893e.pdf. Accessed Nov 2015.
- 15.Donald G, McNeil Jr. Curing Hepatitis C, in an experiment the size of Egypt. New York Times. 2015. https://www.nytimes.com/2015/12/16/health/hepatitis-c-treatment-egypt.html. Accessed Mar 2016.
- 16.Maggie F, Ben H. Gilead offers Egypt new hepatitis C drug at 99 percent discount. Reuters. 2014. http://www.reuters.com/article/us-hepatitis-egypt-gilead-sciences-idUSBREA2K1VF20140321. Accessed Mar 2016.
- 19.World Health Organization. Fact sheet N°134: Traditional medicine. http://www.who.int/mediacentre/factsheets/2003/fs134/en/. Accessed Nov 2016.
- 20.U.S. Food and Drug Administration. 50 years: The Kefauver-Harris Amendments. 2016. http://www.fda.gov/drugs/newsevents/ucm320924.htm. Accessed Feb 2016.
- 21.Medicines and Healthcare products Regulatory Agency. Press release: Yellow Card Scheme looks to the future at 50th anniversary forum. 2014. https://www.gov.uk/government/news/yellow-card-scheme-looks-to-the-future-at-50th-anniversary-forum.
- 22.Uppsala Monitoring Centre. Members of the WHO Programme for International Drug Monitoring. https://www.who-umc.org/global-pharmacovigilance/members/who-programme-members/. Accessed Sept 2017.
- 25.Uppsala Monitoring Centre. Annual Report 2015. http://www.who-umc.org/graphics/30657.pdf. Accessed Mar 2016.
- 27.Worldometers. Africa population. http://www.worldometers.info/world-population/africa-population/. Accessed Sept 2017.
- 28.Ampadu HH, Hoekman J, de Bruin ML, Pal SN, Olsson S, Sartori D, Leufkens HG, Dodoo AN. Adverse drug reaction reporting in Africa and a comparison of individual case safety report characteristics between Africa and the rest of the world: analyses of spontaneous reports in VigiBase®. Drug Saf. 2016;39:335–45.CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Kuemmerle A, Dodoo AN, Olsson S, Van Erps J, Burri C, Lalvani PS. Assessment of global reporting of adverse drug reactions for antimalarials, including artemisinin-based combination therapy, to the WHO Programme for International Drug Monitoring. Malar J. 2011;. https://doi.org/10.1186/1475-2875-10-57.PubMedPubMedCentralCrossRefGoogle Scholar
- 30.Bawazir SA. Attitude of community pharmacists in Saudi Arabia towards adverse drug reaction reporting. Saudi Pharm J. 2006;14:75–83.Google Scholar
- 34.World Health Organization. WHO Pharmaceuticals Newsletter 2000, No. 03: Feature: Direct reporting by consumers—First international conference, Sigtuna, Sweden. http://apps.who.int/medicinedocs/fr/d/Jh1465e/4.html. Accessed Apr 2016.
- 38.World Health Organization. Assessment of medicines regulatory systems in sub-Saharan African countries: an overview of findings from 26 assessment reports. http://apps.who.int/medicinedocs/documents/s17577en/s17577en.pdf. Accessed Jan 2016.
- 39.Strengthening Pharmaceutical Systems (SPS) Program. Safety of medicines in Sub-Saharan Africa: assessment of pharmacovigilance systems and their performance. 2011. http://apps.who.int/medicinedocs/documents/s19152en/s19152en.pdf. Accessed Jan 2016.
- 40.Moscou K, Kohler J, Lexchin J. Drug safety and corporate governance. Glob Health Gov. 2013;7:56–79.Google Scholar
- 41.Buckley GJ, Gostin LO. Countering the problem of falsified and substandard drugs. Washington (DC): Institute of Medicine of the National Academies Press (2013). Accessed Oct 2016.Google Scholar
- 42.Polgreen L. 84 children are killed by medicine in Nigeria. New York Times. 2009. http://www.nytimes.com/2009/02/07/world/africa/07nigeria.html. Accessed Mar 2016.
- 43.World Health Organization. Alert No. 125: Contaminated Isotab® (isosorbide mononitrate) incident in Lahore Pakistan. 2012. http://www.who.int/medicines/publications/drugalerts/DrugSafetyAlert125.pdf. Accessed Apr 2016.
- 46.Glass BD. Counterfeit drugs and medical devices in developing countries. Dove Press J: Res Rep Trop Med. 2014;5:11–22.Google Scholar